Evidence map›Paper›PMID 40748381›Full record

ReviewVirchows Archiv : an international journal of pathology2025

Atypical lymphoproliferations associated with germline genetic variants: a report of the 2024 EA4HP/SH lymphoma workshop.

Michiel van den Brand, Lívia Rásó-Barnett, Gorana Gasljevic, Olga Balague, Camille Laurent, Maurilio Ponzoni, Ioannis Anagnostopoulos, James R Cook, Stefan Dirnhofer, Leticia Quintanilla-Martinez and 2 more

Abstract readReview
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michiel van den BrandPathology-DNA, Location Rijnstate Hospital, Wagnerlaan 55, 6815 AD, Arnhem, the Netherlands. mvandenbrand@rijnstate.nl.ORCID http://orcid.org/0000-0001-8871-6254
Lívia Rásó-BarnettThe Haematopathology and Oncology Diagnostic Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID http://orcid.org/0009-0004-3118-8824
Gorana GasljevicDepartment of Pathology, Institute of Oncology Ljubljana, Zaloska Cesta 2, 1000, Ljubljana, Slovenia.ORCID http://orcid.org/0000-0002-8332-3627
Olga BalagueDepartment of Pathology, Hospital Clínic, Barcelona, Spain.ORCID http://orcid.org/0000-0002-5099-3675
Camille LaurentDepartment of Pathology, Cancer Institute, Toulouse University Hospital Center, University of Toulouse-Oncopole, Toulouse, France.ORCID http://orcid.org/0000-0002-5375-7512
Maurilio PonzoniVita-Salute San Raffaele University, Hematopathology Diagnostic Area, San Raffaele Scientific Institute, Pathology Unit, Milan, Italy.ORCID http://orcid.org/0000-0002-0055-325X
Ioannis AnagnostopoulosInstitute of Pathology, Julius-Maximilians-University Würzburg, Würzburg, Germany.ORCID http://orcid.org/0000-0002-5043-6043
James R CookDepartment of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0003-0456-8085
Stefan DirnhoferInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0009-0008-5250-3159
Leticia Quintanilla-MartinezInstitute of Pathology and Neuropathology, Eberhard-Karls-University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0001-7156-5365
Birgitta SanderDepartment of Laboratory Medicine, Division of Pathology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-1214-1340
Stefania PittalugaLaboratory of Pathology, Center for Cancer Research, Hematopathology Section, National Cancer Institute, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-7688-1439

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Session 2 of the 2024 European Association for Haematopathology/Society for Hematopathology lymphoma workshop was dedicated to atypical lymphoproliferations in association with germline genetic variants. The first group of cases were lymphoproliferations occurring in the context of primary immunodeficiencies (PID), a heterogeneous group of diseases with increasing incidence and number of different diseases due to better recognition. The workshop contained a spectrum of different PIDs and associated lymphoproliferations with autoimmune lymphoproliferative syndrome, activated phosphoinositide 3-kinase delta syndrome, ataxia-telangiectasia and common variable immune deficiency being the most common. Both children and adults were affected, and the diagnosis of an underlying PID often required a high index of suspicion and correlation with clinical presentation and immunological/ infectious workup. Recognition of a PID allows specific treatment and can influence the interpretation of lymphoproliferations occurring in this context. The spectrum of lymphoproliferations ranged from reactive to overt lymphoma, both EBV-positive and -negative. In a subset of cases, it was very difficult or impossible to establish the boundary between reactive and neoplastic in the context of a PID. The second group represented a heterogeneous group of lymphoproliferations in the context of mutations in germline haematopoietic malignancy risk genes, without associated immunodeficiency. It was often difficult to determine if the genetic defect and the lymphoproliferation were causally related or coincidental, especially if the patient was also treated for non-lymphoid conditions. This is a rapidly evolving field in which future studies are expected to shed more light on the relationship between germline mutations and lymphoid malignancy.

Indexed as

Germ-Line MutationLymphomaLymphoproliferative DisordersPrimary Immunodeficiency DiseasesAdultGenetic Predisposition to DiseaseHumansGermline mutationLymphomaPathologyPrimary immunodeficiency

Identifiers

PMID40748381
PMCPMC12391220

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.